321435-99-8

Basic information

• Product Name: 7-Bromo-2,3,4,5-tetrahydro-1H-benzo[b]azepine hydrochloride
• Synonyms: 7-Bromo-2,3,4,5-tetrahydro-1H-benzo[b]azepine hydrochloride;7-Bromo-2,3,4,5-tetrahydro-1H-benzo[b]azepine
• CAS NO: 321435-99-8
• Molecular Formula: C₁₀H₁₂BrN
• Molecular Weight: 262.57392
• Mol File: 321435-99-8.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 318.8±31.0 °C(Predicted)
• Appearance: /
• Density: 1.360±0.06 g/cm3(Predicted)
• PKA: 4.40±0.20(Predicted)
• CAS DataBase Reference: 7-Bromo-2,3,4,5-tetrahydro-1H-benzo[b]azepine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Bromo-2,3,4,5-tetrahydro-1H-benzo[b]azepine hydrochloride(321435-99-8)
• EPA Substance Registry System: 7-Bromo-2,3,4,5-tetrahydro-1H-benzo[b]azepine hydrochloride(321435-99-8)

Safety Data

• Hazardous Substances Data: 321435-99-8(Hazardous Substances Data)

Upstream product

• 87-25-2 2-ethoxycarbonylaniline 
• 120572-43-2 diethyl ester of succinoylanthranilic acid 
• 137046-56-1 5-Brom-2<(4-ethoxy-1,4-dioxobutyl)amino>benzoesaeureethylester 
• 4424-80-0 2,3,4,5-tetrahydro-1H-1-benzo[b]azepin-2-one 
• 1701-57-1 2,3,4,5-tetrahydro-1Hbenzo[b]azepine 
• 3470-53-9 6-amino-1-tetralone 
• 66361-68-0 (E)-6-bromo-3,4-dihydronaphthalen-1(2H)-one oxime 
• 66361-67-9 6-bromo-3,4-dihydro-2H-naphthalen-1-one 
• 201230-82-2 carbon monoxide 
• 267002-57-3 2-allyl-4-bromoaniline 
• 137046-58-3 7-bromo-3,4-dihydro-1H-1-benzazepine-2,5-dione 

Relevant articles and documents

Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model

Histone deacetylase 6 (HDAC6) is a promising therapeutic target for the treatment of neurodegenerative disorders. SW-100 (1a), a phenylhydroxamate-based HDAC6 inhibitor (HDAC6i) bearing a tetrahydroquinoline (THQ) capping group, is a highly potent and sel

BIARYL-CONTAINING COMPOUNDS AS INVERSE AGONISTS OF ROR-GAMMA RECEPTORS

The present invention relates to biaryl-containing inverse agonists of ROR-gamma receptors. The invention also provides pharmaceutical compositions comprising these biaryl- containing inverse agonists, and methods of modulating ROR-gamma receptors using these inverse agonists. Also provided are methods of using biaryl-containing inverse agonists to treat ROR-gamma mediated diseases.

LXR modulators

A compound of formula I wherein A, X, q, R1, R2a, R2b, R2c, R3a, and R3b are defined herein.